Etoposide Injection and Fluorouracil Injection Receive FDA Approval in the United States
February 26, 2026
Source: drugdu
27
Huiyu Pharmaceutical announced on February 25th that it recently received notification from the U.S. Food and Drug Administration (FDA) that its New Drug Applications (NDAs) for etoposide injection and fluorouracil injection have been approved. This means the company can now manufacture and sell these products in the U.S. market through its overseas partners. Etoposide injection is a topoisomerase inhibitor, used in conjunction with other chemotherapy and/or immunotherapy treatments. When used in combination, this treatment is indicated for the following adult patients: 1. Refractory testicular cancer; 2. Small cell lung cancer. Fluorouracil injection is indicated for the treatment of: 1. Colon and rectal cancer; 2. Breast cancer; 3. Gastric adenocarcinoma; 4. Pancreatic cancer.
https://finance.eastmoney.com/a/202602253654068331.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Qilu Pharmaceutical achieves another breakthrough in internationalization, with its blockbuster anti-tumor drug bevacizumab approved for marketing in the UK. February 26, 2026
- Jikeqin’s marketing application accepted by the drug regulatory authority February 26, 2026
- Net profit surged by 1041%, marking a breakthrough for the self-exempt king February 26, 2026
- Kanghong Pharmaceutical’s Class 1 new drug receives clinical trial approval February 26, 2026
- Bio-Thera Solutions’ innovative drug, Darpubayimab injection, has had its marketing authorization application accepted by the NMPA February 25, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
